Thomas Bomhoff - Novozymes Head of Investor Relations
NVZMF Stock | USD 52.51 1.94 3.56% |
Executive
Thomas Bomhoff is Head of Investor Relations of Novozymes AS B
Phone | 45 44 46 00 00 |
Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Daryl Roberts | Dupont De Nemours | 55 | |
Chancey Hagerty | PPG Industries | 50 | |
William Pellicciotti | Air Products and | 44 | |
Kevin Walling | PPG Industries | 59 | |
Karl Schmitt | Sherwin Williams Co | N/A | |
Alexa Dembek | Dupont De Nemours | N/A | |
Roger Dewing | Air Products and | N/A | |
David Bingenheimer | Ecolab Inc | N/A | |
Jeffrey Davies | PPG Industries | N/A | |
Evgeny An | Air Products and | N/A | |
Malesia Dunn | PPG Industries | N/A | |
Marvin Mendoza | PPG Industries | N/A | |
Mary Afflerbach | Air Products and | N/A | |
William Schaupp | PPG Industries | N/A | |
Simon Moore | Air Products and | N/A | |
Joanne Mullen | Ecolab Inc | N/A | |
Irene Tasi | PPG Industries | N/A | |
Christopher Mecray | Dupont De Nemours | N/A | |
Randy Koch | PPG Industries | N/A | |
Jaime Irick | PPG Industries | 50 | |
Katie McDonald | Air Products and | N/A |
Management Performance
Return On Equity | 0.28 | |||
Return On Asset | 0.11 |
Novozymes AS B Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
Tobias Bjorklund, Head of Investor Relations | ||
Ester Baiget, Pres CEO | ||
Kasim Kutay, Director | ||
Anders Lund, Executive Vice President Household Care & Technical Industries | ||
Agnete RaaschouNielsen, Director | ||
Thomas Nagy, Executive VP of Supply Operations | ||
Pedro Fernandes, Head America | ||
Joergen Rasmussen, Independent Director | ||
Andrew Fordyce, Executive VP of Food and Beverages | ||
Lena Halskov, Director, Employee Representative | ||
Tue Micheelsen, VP Marketing | ||
Sebastian Sderberg, VP Acquisitions | ||
Martin Riise, Head of Investor Relations | ||
Peder Nielsen, CEO and Pres | ||
Prisca HavranekKosicek, CFO | ||
HeinzJuergen Bertram, Independent Director | ||
Benny Loft, CFO and Executive VP | ||
Anders Knudsen, Director, Employee Representative | ||
Lena Olving, Independent Director | ||
Mathias Uhlen, Independent Director | ||
Graziela Malucelli, Supply Operations | ||
Patricia Malarkey, Director | ||
Henrik Gurtler, Chairman of the Board | ||
Per Falholt, Consultant | ||
Kim Stratton, Director | ||
Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
Lena Holskov, Director, Employee Representative | ||
Morten Rasmussen, Sustainability People | ||
Thomas Bomhoff, Head of Investor Relations | ||
Lars Green, Director | ||
MSc MSc, Ex CFO | ||
Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.28 | |||
Return On Asset | 0.11 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.26 % | |||
Current Valuation | 14.47 B | |||
Shares Outstanding | 222.86 M | |||
Shares Owned By Insiders | 8.04 % | |||
Shares Owned By Institutions | 42.30 % | |||
Price To Earning | 33.38 X | |||
Price To Book | 6.19 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novozymes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novozymes' short interest history, or implied volatility extrapolated from Novozymes options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |